Schiff Hardin Advises on Public Offerings in Pharma, Tech Sectors
The firm advised Dawson James Securities, Inc., as placement agents in Sonoma Pharmaceuticals, Inc’s public offering of 1.4 million shares of common stock, raising $4.6 million. Schiff Hardin then advised ViewTrade Securities, Inc. as the underwriter in Senmiao Technology Limited’s IPO of 3 million shares of common stock, raising $12 million.
Schiff Hardin also advised The Benchmark Company as managing underwriter in Biofrontera AG’s IPO of 1.2 million American depositary shares (ADSs), raising $12 million, and the Nasdaq listing of Biofrontera’s ADSs. The shareholders of the dermatology-focused biotechnology company have pre-emptive rights under German law and Biofrontera’s shares already traded on the Frankfurt Stock Exchange, making this a very complex transaction. The transaction involved side-by-side U.S. and German pre-emptive rights offerings.
Contacts
-
Contact:
Nathan Carlile, Head of Firmwide Communications
- Related Industries
- Related Practices